Jazz Pharmaceuticals plc 4

EVP Robert Iannone of Jazz Pharmaceuticals exercised options for 57,500 ordinary shares and sold 77,921 ordinary shares on August 27, 2026 under a Rule 10b5-1 plan.

On August 27, 2026, Jazz Pharmaceuticals plc EVP, Global Head of R&D & CMO Robert Iannone exercised multiple tranches of stock options (both incentive and non-qualified) at strike prices of $113.10 and $137.12, acquiring a total of 57,500 ordinary shares, and on the same day sold 77,921 ordinary shares in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan at weighted average prices ranging from approximately $247.86 to $252.76 per share. The option exercises appear to be cashless or net-share related (reported at $0.0 in the derivative line items) and were followed by sales that monetized a significant portion of the newly acquired shares while still leaving Iannone with 65,686 ordinary shares in direct ownership after the transactions. Based on the disclosed prices, the gross value of the option exercises was roughly $7.1 million, while the gross value of the share sales was approximately $19.4 million, indicating a sizable, but pre-planned, liquidity event aligned with the vesting schedule under the issuer’s 2011 Equity Incentive Plan.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0001737329-26-000016

Alert Tier

7